Ham, In-Hye
Oh, Hye Jeong
Jin, Hyejin
Bae, Cheong A
Jeon, Sang-Min
Choi, Kyeong Sook
Son, Sang-Yong
Han, Sang-Uk
Brekken, Rolf A.
Lee, Dakeun
Hur, Hoon
Funding for this research was provided by:
National Research Foundation (2014R1A1A2057390, 2017R1C1B2003970)
National Research Foundation (2018R1A6A3A01012164)
Ministry of Health and Welfare (HI17C0364)
Korean Foundation for Cancer Research (KFCR-2015-001)
Article History
Received: 15 October 2018
Accepted: 21 February 2019
First Online: 30 March 2019
Ethics approval and consent to participate
: This study was approved by the institutional review board/ethics committee of the Ajou University Hospital (AJIRB-BMR-KSP-15-432).
: Not applicable.
: R.A. Brekken has an ownership interest (including stock, patents, etc.) in and is a consultant/advisory board member for Tuevol Therapeutics. Other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.